Baldwin Brothers Inc. MA Sells 2,096 Shares of Sanofi SA (NYSE:SNY)

Share on StockTwits

Baldwin Brothers Inc. MA decreased its position in shares of Sanofi SA (NYSE:SNY) by 20.2% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,295 shares of the company’s stock after selling 2,096 shares during the period. Baldwin Brothers Inc. MA’s holdings in Sanofi were worth $359,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in SNY. Patten Group Inc. increased its holdings in shares of Sanofi by 3.5% in the second quarter. Patten Group Inc. now owns 7,179 shares of the company’s stock worth $311,000 after buying an additional 240 shares during the period. OLD National Bancorp IN increased its holdings in shares of Sanofi by 2.4% in the first quarter. OLD National Bancorp IN now owns 11,434 shares of the company’s stock worth $506,000 after buying an additional 271 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its holdings in shares of Sanofi by 11.5% in the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 2,772 shares of the company’s stock worth $123,000 after buying an additional 286 shares during the period. Global Retirement Partners LLC increased its holdings in shares of Sanofi by 28.0% in the first quarter. Global Retirement Partners LLC now owns 1,331 shares of the company’s stock worth $59,000 after buying an additional 291 shares during the period. Finally, Moors & Cabot Inc. increased its holdings in shares of Sanofi by 4.1% in the second quarter. Moors & Cabot Inc. now owns 7,757 shares of the company’s stock worth $336,000 after buying an additional 302 shares during the period. Institutional investors and hedge funds own 7.04% of the company’s stock.

NYSE SNY opened at $41.65 on Friday. The business’s 50-day moving average is $42.22 and its 200 day moving average is $42.62. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.22 and a quick ratio of 0.85. The stock has a market capitalization of $103.37 billion, a PE ratio of 13.31, a PEG ratio of 2.41 and a beta of 0.67. Sanofi SA has a 1 year low of $40.00 and a 1 year high of $45.62.

Sanofi (NYSE:SNY) last posted its quarterly earnings data on Monday, July 29th. The company reported $0.74 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.67 by $0.07. The business had revenue of $8.63 billion for the quarter, compared to analysts’ expectations of $8.42 billion. Sanofi had a return on equity of 18.18% and a net margin of 12.20%. The business’s revenue was up 5.5% on a year-over-year basis. During the same period in the previous year, the firm posted $1.25 EPS. As a group, equities research analysts anticipate that Sanofi SA will post 3.1 earnings per share for the current year.

In other news, major shareholder Sanofi acquired 93,750 shares of the business’s stock in a transaction on Monday, July 22nd. The shares were acquired at an average cost of $16.00 per share, with a total value of $1,500,000.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 1.00% of the company’s stock.

SNY has been the topic of several analyst reports. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Sanofi in a report on Tuesday, August 6th. UBS Group upgraded Sanofi from a “neutral” rating to a “buy” rating in a report on Wednesday. Finally, TheStreet upgraded Sanofi from a “c+” rating to a “b-” rating in a report on Friday, June 21st. Seven analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $51.00.

About Sanofi

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Featured Article: What is a Roth IRA?

Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.